A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention

Health Policy

Volumn 101, Issue 3, 2011, Pages 290-299

  Fischer, Katharina E ^a   Leidl, Reiner ^a,b   Rogowski, Wolf H ^a,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cancer; Decision making; Insurance coverage; Prevention; Reimbursement

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; WART VIRUS VACCINE;

ARTICLE; AUSTRIA; CANCER PREVENTION; CANCER SCREENING; CLINICAL DECISION MAKING; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; COST; FEASIBILITY STUDY; FEMALE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LITHUANIA; PAPILLOMAVIRUS INFECTION; PROSTATE CANCER; PUBLICATION; QUESTIONNAIRE; REIMBURSEMENT; SEMI STRUCTURED INTERVIEW; SWEDEN; VACCINATION;

DECISION MAKING; EARLY DETECTION OF CANCER; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; INSURANCE, HEALTH, REIMBURSEMENT; INTERVIEWS AS TOPIC; NEOPLASMS; POLICY MAKING;

EID: 79960141658     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2011.03.002     Document Type: Article

References (29)

1. Hutton J., McGrath C., Frybourg J.M., Tremblay M., Bramley-Harker E., Henshall C. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). International Journal of Technology Assessment in Health Care 2006, 22:10-18.
2. Leidl R. Promoting economic value in public health. European Journal of Public Health 2008, 18:216.
3. Taylor R.S., Drummond M.F., Salkeld G., Sullivan S.D. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004, 329:972-975.
4. Barbieri M., Hawkins N., Sculpher M. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies. Value Health 2008.
5. Dakin H.A., Devlin N.J., Odeyemi I.A. Yes", "No" or "Yes, but" ? Multinomial modelling of NICE decision-making. Health Policy 2006, 77:352-367.
6. Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004, 13:437-452.
7. Vuorenkoski L., Toiviainen H., Hemminki E. Decision-making in priority setting for medicines: a review of empirical studies. Health Policy 2008, 86:1-9.
8. Anell A. Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees. European Journal of Public Health 2004, 5:28-35.
9. Cairns J. Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy 2006, 76:134-143.
10. Chalkidou K., Tunis S., Lopert R., Rochaix L., Sawicki P.T., Nasser M., et al. Comparative effectiveness research and evidence-based health policy: Experience from four countries. The Milbank Quarterly 2009, 87:339-367.
11. Zentner A., Velasco-Garrido M., Busse R. Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. Informationssystem Health Technology Assessment (HTA) in Deutschland 2005, Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information (DAHTA@DIMDI), Cologne.
12. Rogowski W.H., Hartz S.C., John J.H. Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Services Research 2008, 8:194.
13. Neumann U., Hagen A., Schönermark M. Regulation der Aufnahme von innovativen nichtmedikamentösen Technologien in den Leistungskatalog solidarisch finanzierter Kostenträger. GMS Health Technology Assessment 2007, 3:1-163.
14. Haas M., Ashton T., Blum K., Christiansen T., Conis E., Crivelli L., et al. Drugs, sex, money and power: an HPV vaccine case study. Health Policy 2009, 92:288-295.
15. Meckley L.M., Neumann P.J. Personalized medicine: factors influencing reimbursement. Health Policy 2010, 94:91-100.
16. Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union. European Journal of Cancer 2009, 45:708-2685.
17. Anttila A., von Karsa L., Aasmaa A., Fender M., Patnick J., Rebolj M., Nicula F., Vass L., Valerianova Z., Voti L., Sauvaget C., Ronco G. Cervical cancer screening policies and coverage in Europe. European Journal of Cancer 2009, 45:58-2649.
18. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008.
19. Gutierrez-Ibarluzea I., Asua J., Latorre K. Policies of screening for colorectal cancer in European countries. International Journal of Technology Assessment in Health Care 2008, 24:6-270.
20. Holland W., Stewart S. Screening in Disease Prevention: What Works? London: Radcliffe Publishing Ltd 2005.
21. Schreyögg J., Stargardt T., Velasco-Garrido M., Busse R. Defining the "Health Benefit Basket" in nine European countries. Evidence from the European Union Health BASKET Project. Eur J Health Econ 2005, (Suppl):2-10.
22. Williams I., McIver S., Moore D., Bryan S. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess 2008, 12. iii ix-x 1-175.
23. Glenngard A, Hjalte F, Svensson M, Anell A, Bankauskaite V, Health Systems in Transition - HiT Summary Sweden. In: Policies EOoHSa, editor. Health Systems in Transition. Copenhagen, 2005.
24. Hofmarcher M.M., Rack H.-M. Austria: Health system review. Health Systems in Transition 2006, 8:1-247.
25. Krukiene G, Alonderis T, Pharmaceutical Pricing and Reimbursement Information - Lithuania Pharma Profile. In: European Commission HaCPD-G, Austrian Ministry of Health, Family and Youth, editor. PPRI, 2008.
26. Carlsson P. Health technology assessment and priority setting for health policy in Sweden. Int J Technol Assess Health Care 2004, 20:44-54.
27. Bekkering G.E., Kleijnen J. Procedures and methods of benefit assessments for medicines in Germany. Eur J Health Econ 2008, 9(Suppl 1):5-29.
28. European Medicines Agency. Gardasil - Scientific Discussion. London, 2006.
29. European Medicines Agency. Cervarix - Scientific Discussion. London, 2007.